U.S. Study sites must be starting soon......and it's only February.
With preliminary treatments happening in March or April, and second treatments by mid-summer, we should have a harvest of results in the fall!
And with treatments having been adjusted and optimized, we'll surely see more and more CR, like patients 5 and 6 of Phase1 !
Realistically, all we need to become the new standard of care is a 20-30% success rate, since this treatment is far simpler and cheaper than immunology. We're taking over this market in two years.
But, also realistically, the odds are very good that we'll be in the 66-70% range needed for FDA breakthrough designation!
And then there's lung, and glioblastoma, and breast, and Covid treatment, and...
The sky ain't the limit, boys... There is no limit!
Don't let the stop-loss trigger-monkeys upset you, just keep buying at these low levels!
All IMNSHO, of course!
GLTA TLT sages!